Overview

Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the potential of using valsartan/HCTZ as initial therapy in patients with severe hypertension compared to valsartan alone as initial therapy, and to determine whether a greater proportion of patients achieve blood pressure control with the combination compared to the monotherapy without producing an unacceptable adverse event profile.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Hydrochlorothiazide
Valsartan